Moreover, we showed that at least two mechanisms can lead to pathological ERBB2 overexpression in breast cancer: ERBB2 gene amplification and increased transcription through high levels of transcriptional activators, such as AP-2α and YY1. Here, YY1 is linked to breast carcinoma.